"But do Epigentics, and/or BET Inhibition in general and Apabetalone in particluar target "Cardiometabolic Risk"?"

The populations with the largest relative risk reductions in the post-hoc analyses of ASSERT, SUSTAIN and ASSURE Phase 2 trials were those with diabetes and increased inflammation. That is a very cardiometabolic risk population. So yes, apabetalone targets cardiometabolic risk. Furthermore, much of the article discusses various LDL lowering therapies. So if LDL lowering is cardiometabolic, then apoAI-HDL elevating sure is cardiometabolic. In other words, cardiometabolic encompasses a lot of risk factors.

BDAZ